Top 10 CRISPR Stocks To Buy

Published on April 20, 2023 at 6:24 pm by Hamna Asim in Hedge Funds, News

In this article, we discuss the top 10 CRISPR stocks to buy. If you want to see more stocks in this selection, check out Top 5 CRISPR Stocks To Buy.

Molecular biology, genetics, and genomics are in a significant period in history where technical capabilities and methods enable the editing of specific DNA segments and base pairs in living organisms and cells. The convergence of clustered regularly interspaced short palindromic repeat (CRISPR) genome editing, along with advancements in computing and imaging technology, has ushered in a new era where scientists can diagnose and predict human diseases based on personal genetics, as well as take action on this information. Over the last decade, RNA-programmed genome editors have been discovered, engineered, and used in various applications. These editors use the fundamental ability of CRISPR-Cas9 to create targeted genetic disruptions in genes or gene regulatory elements, leading to successful creation of knockout mice and other animal models, genetic screening, and multiplexed editing. In addition to traditional CRISPR-Cas9 knockouts, the use of base editing, which involves engineered Cas9 enzymes that can modify the chemical structure of DNA bases, has proven to be a useful strategy for generating specific and precise point mutations at desired sites.

According to Allied Market Research, in 2021, the gene editing market worldwide had a value of $3.9 billion, and it is expected to grow at a compound annual growth rate (CAGR) of 6.7% from 2022 to 2031, reaching a value of $7.4 billion by 2031. Genomics can be applied in various fields such as identifying human genetic abnormalities, drug discovery, agriculture, veterinary sciences, and forensics. There have been significant developments in the CRISPR space. For example, a one-time gene editing therapy developed by Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and CRISPR Therapeutics AG (NASDAQ:CRSP) for treating sickle cell disease could be considered cost-effective if priced at a maximum of $1.9 million. The companies are seeking approval for the world’s first therapy that utilizes the Nobel prize-winning CRISPR technology, to treat two types of blood disorders – sickle cell disease and transfusion-dependent beta thalassemia.

Cathie Wood, the founder of ARK Invest who is known for her innovative and disruptive investment strategies, focuses on technologies such as robotics, artificial intelligence, and genomics. Cathie Wood stated in a 2018 video that “monogenic stem cell therapy” could generate $2 trillion in revenue, while “polygenic” versions of the therapy could be worth “many trillions” more. This is one example of the bold statements Wood frequently makes. In recent months, Wood has had to defend her investment strategy after many of the companies in her funds were heavily impacted by a significant market correction.

On January 4, 2023, Wood mentioned a BBC news article that reported on Alyssa, a patient diagnosed with T-cell acute lymphoblastic leukemia, who was successfully treated with the help of base editing by doctors at Great Ormond Street Hospital. Despite this breakthrough, Wood noted that the news was overshadowed by the financial market downturn in 2022, and some analysts are even disregarding the technology’s potential. Elon Musk also favored Wood’s stance on the gene editing market outlook. Markets Insider cited Cathie Wood, who noted that investors are fleeing from gene editing stocks given their downward market performance:

“In our view, US equity markets today are 180 degrees away from those in the tech and telecom bubble in the late nineties. Unlike the case then, the technologies are ready and the costs are low enough for prime time. Investors chased the dream then. Now, they are running away.”

Some of the best CRISPR stocks to buy in order to benefit from this emerging sector include CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Investors can also check out 11 Most Promising Gene Editing Stocks and 10 Most Promising Gene Therapy Companies.

Photo by CDC on Unsplash

Our Methodology

We scanned Insider Monkey’s database of 943 hedge funds and picked the top 10 companies that provide services in the CRISPR market with the highest number of hedge fund investors. These are the best CRISPR stocks to buy according to hedge funds.

Top CRISPR Stocks to Buy

10. Twist Bioscience Corporation (NASDAQ:TWST)

Number of Hedge Fund Holders: 17

Twist Bioscience Corporation (NASDAQ:TWST) is a company that deals with synthetic biology, producing and vending synthetic DNA-based products. Twist Bioscience Corporation (NASDAQ:TWST)’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. Their selection of products includes synthetic genes, sample preparation tools, antibody libraries for developing and discovering drugs, and DNA as a form of digital data storage.

On February 6, Catherine Ramsey Schulte, an analyst at Baird, maintained an Outperform rating on Twist Bioscience Corporation (NASDAQ:TWST) but reduced the price target on the shares from $33 to $29. The analyst stated that although there are some areas of short-term weakness as the company begins to increase commercial volumes in their Factory of the Future, management remains positive about their primary business. The analyst also indicated that the company’s revenue guidance for 2023 remains unchanged.

According to Insider Monkey’s fourth quarter database, 17 hedge funds were long Twist Bioscience Corporation (NASDAQ:TWST), compared to 18 funds in the prior quarter. Cathie Wood’s ARK Investment Management held the largest stake in the company, with 6.70 million shares worth $159.5 million.

Like CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Twist Bioscience Corporation (NASDAQ:TWST) is one of the best CRISPR stocks to watch.

Jackson Square Partners made the following comment about Twist Bioscience Corporation (NASDAQ:TWST) in its Q3 2022 investor letter:

“Twist Bioscience Corporation (NASDAQ:TWST): market leader in synthetic DNA manufacturing with its highly differentiated silicon platform; poised to unlock a multi-year outsourcing wave as new manufacturing processes and products dramatically improve the turnaround time, cost, and quality of silicon-based DNA manufacturing.”

9. Beam Therapeutics Inc. (NASDAQ:BEAM)

Number of Hedge Fund Holders: 18

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotech company in the US that focuses on the development of genetic medicines for serious diseases. They have research collaborations with Pfizer, Apellis Pharmaceuticals, Verve Therapeutics, Sana Biotechnology, Orbital Therapeutics, and the Institute of Molecular and Clinical Ophthalmology Basel for various diseases such as genetic diseases of the liver, muscle, and central nervous system, cardiovascular disease, impaired vision, and blindness. Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best CRISPR stocks to invest in. On February 28, the company reported a Q4 GAAP EPS of -$0.54 and a revenue of $20.04 million, outperforming Wall Street estimates by $0.81 and $7.31 million, respectively.

On March 21, William Pickering, an analyst at Bernstein, began coverage of Beam Therapeutics Inc. (NASDAQ:BEAM) with a Market Perform rating and a price target of $37. Although the analyst has enthusiasm for the company’s technology, they are unable to meet the consensus estimates without assuming significant revenue from future pipeline assets that have not been identified yet. Therefore, the firm’s estimated revenue from sickle cell disease and most of Beam Therapeutics Inc. (NASDAQ:BEAM)’s other assets fall below the consensus.

According to Insider Monkey’s fourth quarter database, 18 hedge funds were bullish on Beam Therapeutics Inc. (NASDAQ:BEAM), compared to 27 funds in the prior quarter. Thomas Steyer’s Farallon Capital is a prominent stakeholder of the company, with 3.4 million shares worth approximately $133 million.

Here is what Baron Health Care Fund has to say about Beam Therapeutics Inc. (NASDAQ:BEAM) in their Q1 2021 investor letter:

“Beam Therapeutics Inc. is a biotechnology company pioneering a novel technology called base editing, which allows for individual base pairs (the letters of DNA) to be modified. Shares fell along with other biotechnology stocks driven by a sudden rise in treasury yields. Early stage biotechnology stocks are particularly sensitive to interest rates because their cash flows are further in the future. We believe we are entering into a phase of significant advancement for the gene editing field that will eventually lead to curative therapies, and we think Beam has a unique platform technology.”

8. Editas Medicine, Inc. (NASDAQ:EDIT)

Number of Hedge Fund Holders: 20

Editas Medicine, Inc. (NASDAQ:EDIT) is a clinical stage genome editing company, focused on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. It is one of the best CRISPR stocks to invest in.

On February 23, Geulah Livshits, an analyst at Chardan, reduced the price target for Editas Medicine, Inc. (NASDAQ:EDIT) from $35 to $22. Despite this, Livshits maintained a Buy rating on the shares following the fiscal 2022 results. Editas Medicine, Inc. (NASDAQ:EDIT) has reaffirmed its guidance for a data update in the mid-23 on EDIT-301, an ex vivo gene-edited hematopoietic stem cell therapy for sickle cell disease. According to the analyst, the company is undergoing a retrenchment phase after stopping internal investments in inherited retinal diseases and preclinical iNK programs.

According to Insider Monkey’s fourth quarter database, 20 hedge funds were bullish on Editas Medicine, Inc. (NASDAQ:EDIT), compared to 21 funds in the prior quarter. Michael Rockefeller and Karl Kroeker’s Woodline Partners is the biggest stakeholder of the company, with 2 million shares worth $18.4 million.

7. Verve Therapeutics, Inc. (NASDAQ:VERV)

Number of Hedge Fund Holders: 23

Verve Therapeutics, Inc. (NASDAQ:VERV) focuses on creating gene editing medications to treat cardiovascular diseases. The company has collaborated with and obtained license agreements from Beam Therapeutics, entered into a development and option agreement with Acuitas Therapeutics, and acquired a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. It is one of the best CRISPR stocks to invest in. On March 2, Verve Therapeutics, Inc. (NASDAQ:VERV) reported a Q4 GAAP EPS of -$0.67 and a revenue of $1.01 million, beating market estimates by $0.09 and $0.57 million, respectively.

Whitney Ijem, an analyst at Canaccord, initiated coverage of Verve Therapeutics, Inc. (NASDAQ:VERV) with a Buy rating and a price target of $29 on April 11. The analyst cited the company’s advanced gene-editing technology, clinically validated non-viral delivery methods, and well-established genetic targets as reasons for the favorable rating. The firm has taken into account some commercial concerns that need to be addressed, but it has made conservative market share assumptions and still sees significant potential for combined peak sales of over $5 billion for the company’s leading programs, VERVE-101 and VERVE-201.

According to Insider Monkey’s fourth quarter database, 23 hedge funds were long Verve Therapeutics, Inc. (NASDAQ:VERV), compared to 18 funds in the prior quarter. Eli Casdin’s Casdin Capital is the largest stakeholder of the company, with 2.3 million shares worth $44.3 million.

6. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Number of Hedge Fund Holders: 25

Pacific Biosciences of California, Inc. (NASDAQ:PACB) manufactures and designs equipment for sequencing that is used to solve problems involving complex genetics. The company offers sequencing systems, as well as consumable products like single molecule real-time (SMRT) cells and specialized reagent kits made for specific workflows. In the fourth quarter of 2022, Pacific Biosciences of California, Inc. (NASDAQ:PACB) received record orders, including orders for 96 instruments, which included orders for 76 Revio systems from 43 customers across 13 countries and representing a wide range of applications.

On March 31, TD Cowen analyst Dan Brennan upgraded Pacific Biosciences of California, Inc. (NASDAQ:PACB) to Outperform from Market Perform with a price target of $15, up from $13. The company is viewed as a “growth transformation story” under the leadership of CEO Christian Henry, and investor sentiment has become more positive. However, the stock’s high multiple and expectations may deter some investors. According to the firm’s customer survey, there is potential for growth in placements and pull through, as well as a shift towards long-read sequencing in budget allocations. TD Cowen believes that it is a good time to invest in this multi-year story, as long-read sequencing technology will become more significant in the genomics and sequencing market, and Pacific Biosciences of California, Inc. (NASDAQ:PACB) is likely to benefit from this trend.

According to Insider Monkey’s fourth quarter database, 25 hedge funds were long Pacific Biosciences of California, Inc. (NASDAQ:PACB), compared to 21 funds in the earlier quarter. Steve Cohen’s Point72 Asset Management is the largest stakeholder of the company, with 5.3 million shares worth $43.6 million.

In addition to CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Pacific Biosciences of California, Inc. (NASDAQ:PACB) is one of the best CRISPR stocks to buy.

Jackson Square Partners made the following comment about Pacific Biosciences of California, Inc. (NASDAQ:PACB) in its Q3 2022 investor letter:

“Pacific Biosciences of California, Inc. (NASDAQ:PACB): emerging player in genomic sequencing with its highly differentiated long-read technology; poised to unlock a multi-year share shift towards long-read sequencing as new products dramatically improve throughput and cost to competitively advantaged levels.”

Click to continue reading and see Top 5 CRISPR Stocks To Buy.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up